Open access
Open access
Powered by Google Translator Translator

Gastroenterology (all articles)

AHA Statement | Indications, evaluation, and outcomes for dual heart-kidney and heart-liver transplantation

14 Jul, 2023 | 12:51h | UTC

Dual-Organ Transplantation: Indications, Evaluation, and Outcomes for Heart-Kidney and Heart-Liver Transplantation: A Scientific Statement From the American Heart Association – Circulation

 


EASL Guidelines on the management of liver diseases in pregnancy

13 Jul, 2023 | 13:05h | UTC

EASL Clinical Practice Guidelines on the management of liver diseases in pregnancy – Journal of Hepatology

 


AASLD Guidance | Use of TIPS, variceal embolization, and retrograde transvenous obliteration in variceal hemorrhage

11 Jul, 2023 | 13:59h | UTC

AASLD Practice Guidance on the Use of TIPS, Variceal Embolization, and Retrograde Transvenous Obliteration in the Management of Variceal Hemorrhage – Hepatology

 


Guideline | Acute liver failure

10 Jul, 2023 | 13:59h | UTC

Acute Liver Failure Guidelines – The American Journal of Gastroenterology

Related:

EASL Clinical Practice Guidelines on acute-on-chronic liver failure – Journal of Hepatology

Guidelines for the management of adult acute and acute-on-chronic liver failure in the ICU

Acute-on-chronic liver failure: far to go—a review – Critical Care

 


RCT | Mirikizumab outperforms placebo in inducing and maintaining remission in ulcerative colitis

10 Jul, 2023 | 13:25h | UTC

Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: Mirikizumab Bests Placebo in Treating Patients With Ulcerative Colitis – HCP Live

 

Commentary on Twitter

 


Review | Acute-on-chronic liver failure

7 Jul, 2023 | 16:09h | UTC

Acute-on-chronic liver failure: far to go—a review – Critical Care

Related:

EASL Clinical Practice Guidelines on acute-on-chronic liver failure – Journal of Hepatology

Guidelines for the management of adult acute and acute-on-chronic liver failure in the ICU

 


From NAFLD to MASLD | New consensus changes fatty liver disease terminology to avoid stigmatization

30 Jun, 2023 | 15:01h | UTC

A multi-society Delphi consensus statement on new fatty liver disease nomenclature – Hepatology

 

Commentary on Twitter

 


Phase 2 RCT | FGF21 analogue Pegozafermin treatment leads to improvement in NASH fibrosis

30 Jun, 2023 | 14:58h | UTC

Summary: In a phase 2b, multicenter, double-blind, randomized, placebo-controlled trial, the fibroblast growth factor 21 (FGF21) analogue pegozafermin was examined for its efficacy and safety in treating patients with biopsy-confirmed noncirrhotic nonalcoholic steatohepatitis (NASH). A total of 222 patients with moderate or severe fibrosis (stage F2 or F3) were assigned to receive either subcutaneous pegozafermin at varying doses or a placebo. The primary endpoints were an improvement in fibrosis and resolution of NASH without worsening of fibrosis at 24 weeks.

The results showed that a larger percentage of patients receiving pegozafermin met the criteria for fibrosis improvement and NASH resolution compared to those receiving placebo. The most significant improvements were observed in the 44-mg pegozafermin group, with 27% showing fibrosis improvement and 26% meeting NASH resolution criteria, compared to 7% and 2% in the placebo group, respectively. Adverse events were mainly gastrointestinal and included nausea and diarrhea. These findings support the progression of pegozafermin into phase 3 development.

Article: Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH – New England Journal of Medicine (link to abstract – $ for full-text)

 

Commentary on Twitter

 


Guidance on fecal immunochemical testing to help diagnose colorectal cancer among symptomatic patients in primary care

29 Jun, 2023 | 13:59h | UTC

Guidance on faecal immunochemical testing (FIT) to help diagnose colorectal cancer among symptomatic patients in primary care – British Journal of General Practice

Related: Faecal immunochemical testing (FIT) in patients with signs or symptoms of suspected colorectal cancer (CRC): a joint guideline from the Association of Coloproctology of Great Britain and Ireland (ACPGBI) and the British Society of Gastroenterology (BSG) – Gut

 


Liver Transplantation 2023 | Status report, current and future challenges

29 Jun, 2023 | 13:50h | UTC

Liver Transplantation 2023: Status Report, Current and Future Challenges – Clinical Gastroenterology and Hepatology

 


RCT | Bulevirtide reduces HDV RNA and ALT levels in chronic hepatitis D patients

28 Jun, 2023 | 13:20h | UTC

Summary: This randomized phase 3 trial evaluated the efficacy of bulevirtide, an inhibitor of HDV entry into hepatocytes, in patients with chronic hepatitis D. Patients were randomized to receive either 2 mg or 10 mg of bulevirtide daily for 144 weeks, or no treatment for 48 weeks followed by 10 mg bulevirtide daily for 96 weeks. The study involved 150 patients, 49 in the 2-mg group, 50 in the 10-mg group, and 51 in the control group.

After 48 weeks of treatment, 45% and 48% of patients in the 2-mg and 10-mg groups respectively achieved the primary end point of undetectable HDV RNA level or a decrease of at least 2 log10 IU per milliliter from baseline, and normalization of ALT level. Only 2% in the control group reached the primary endpoint. ALT levels normalized in 51% and 56% of patients in the 2-mg and 10-mg groups respectively, a significant difference from the 12% normalization in the control group. Notably, loss of HBsAg did not occur by week 48 in the bulevirtide groups. No serious adverse events related to the treatment were reported, though side effects including headache, pruritus, and fatigue were more common in the bulevirtide groups.

These results demonstrate the effectiveness of bulevirtide in reducing HDV RNA and ALT levels in patients with chronic hepatitis D. However, the absence of HBsAg loss in bulevirtide groups raises questions about its long-term implications.

Article: A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D – New England Journal of Medicine (link to abstract – $ for full-text)

 

Commentary on Twitter

 


EASL Clinical Practice Guidelines on acute-on-chronic liver failure

27 Jun, 2023 | 14:00h | UTC

EASL Clinical Practice Guidelines on acute-on-chronic liver failure – Journal of Hepatology

 

Commentary on Twitter

 


Consensus Paper | Gut microbiota and fecal microbiota transplantation in inflammatory bowel disease

26 Jun, 2023 | 00:26h | UTC

The first international Rome consensus conference on gut microbiota and faecal microbiota transplantation in inflammatory bowel disease – Gut

 


Cohort Study | Dengue patients at high risk of cholecystitis and pancreatitis within 30 days

21 Jun, 2023 | 13:34h | UTC

Risks of Acute Cholecystitis, Acute Pancreatitis, and Acute Appendicitis in Patients with Dengue Fever: A Population-Based Cohort Study in Taiwan

 


Review | Update in the treatment of the complications of cirrhosis

21 Jun, 2023 | 13:20h | UTC

Update in the Treatment of the Complications of Cirrhosis – Clinical Gastroenterology and Hepatology

 


Podcast | Inpatient cirrhosis management

20 Jun, 2023 | 12:30h | UTC

# 398:Live! From SHM: Inpatient Cirrhosis Management – The Curbsiders

 


Review | Celiac disease: who should I test, and how?

19 Jun, 2023 | 13:54h | UTC

Celiac disease: Who should I test, and how? – Cleveland Clinic Journal of Medicine

 


Cohort Study | Alcohol consumption and risks of more than 200 diseases in Chinese men

16 Jun, 2023 | 13:55h | UTC

Alcohol consumption and risks of more than 200 diseases in Chinese men – Nature Medicine

News Release: Alcohol consumption increases the risks of over 60 diseases – University of Oxford

 


M-A | Comparing non-invasive tests, histology for predicting non-alcoholic fatty liver outcomes

15 Jun, 2023 | 14:50h | UTC

Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis – The Lancet Gastroenterology & Hepatology

 


Cohort Study | 63.1% of uncomplicated appendicitis in children successfully treated non-operatively at 1 year

15 Jun, 2023 | 14:45h | UTC

Outcomes 1 year after non-operative management of uncomplicated appendicitis in children: Children with AppendicitiS during the CoronAvirus panDEmic (CASCADE) study – BJS Open

 

Commentary on Twitter

 


M-A | Significant non-alcoholic fatty liver disease prevalence in South Asia, many non-obese affected

6 Jun, 2023 | 14:00h | UTC

Prevalence and associated factors for non-alcoholic fatty liver disease among adults in the South Asian Region: a meta-analysis – The Lancet Regional Health – Southeast Asia

 


Cohort Study | Overweight or obesity in early and middle adulthood linked to higher gastrointestinal cancer risk

5 Jun, 2023 | 13:34h | UTC

Analysis of Body Mass Index in Early and Middle Adulthood and Estimated Risk of Gastrointestinal Cancer – JAMA Network Open

Editorial: Obesity and Gastrointestinal Cancer: A Life Course Perspective – JAMA Network Open

Commentary: Association Between Overweight/Obesity and Risk of Gastrointestinal Cancer – The ASCO Post

 


AASLD-IDSA Guideline | Updated 2023 recommendations for the testing, management, and treatment of Hepatitis C virus infection

1 Jun, 2023 | 12:21h | UTC

Hepatitis C Guidance 2023 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection – Clinical Infectious Diseases

 


SR | Systematic review finds 16.4-36.18 severe bleedings, 7.62-8.5 perforations per 10,000 colonoscopies

1 Jun, 2023 | 12:15h | UTC

An Estimate of Severe Harms Due to Screening Colonoscopy: A Systematic Review – The Journal of the American Board of Family Medicine

 


RCT | JAK inhibitor Upadacitinib shows superiority over placebo for moderate-to-severe Crohn’s disease

1 Jun, 2023 | 12:08h | UTC

Upadacitinib Induction and Maintenance Therapy for Crohn’s Disease – New England Journal of Medicine (link to abstract – $ for full-text)

 


Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.